Lung Cancer Considered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC.

Guests:
Kelsey Pan, MD, MPH
Assistant Professor of Medicine
Department of Hematology & Oncology, Thoracic Medical Oncology Section
Emory University Winship Cancer Institute

Rajat Thawani, MD
Assistant Professor of Medicine
Division of Hematology and Oncology
Knight Cancer Institute, OHSU

This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management,

Guests:

Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom.

Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy

This episode examines the role public policy plays in impacting lung cancer treatment and research. The world has made tremendous progress in the treatment of lung cancer over the past decade, and much of that progress is the result of supportive public health policies. As we look to the future, healthcare policy is sure to play an even bigger role in further improving patient outcomes, but many challenging barriers exist on a global scale.

Host: Dr. Stephen Liu
Guests:

Professor Andreas Charalambous, Chair of the Department of Nursing and Professor of Oncology and Palliative Care at the Cyprus University of Technology.

Professor Nicole Rankin, Head of the Evaluation and Implementation Science Unit at the Melbourne School of Population and Global Health of the University of Melbourne

Dr. Samuel Kareff, thoracic medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute and Clinical Assistant Professor at Florida Atlantic University

As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert cardiothoracic surgeons, Dr. Ben Li, Professor from The First Affiliated Hospital of Guangzhou Medical University and, and Dr. Calvin Ng, Professor from the Chinese University of Hong Kong. The discussion: reviews surgical management of early-stage NSCLC, including VATS, and lobar versus sublobar resection; and explores novel technologies including endobronchial therapy and tubeless anesthesia.

Host: Molly Li, MD Clinical Assistant Professor
Department of Clinical Oncology, CUHK, Hong Kong

Guests:
Shuben Li, MD, PhD
Professor, Department of Thoracic Surgery
National Center for Respiratory Medicine
The First Affiliated Hospital of Guangzhou Medical University


Calvin S.H. Ng, BSc MBBS, MD
Environmental Foundation Professor of Thoracic Surgery
Department of Surgery
The Chinese University of Hong Kong (CUHK)

This episode of Lung Cancer Considered examines how artificial intelligence is being incorporated into patient care and what the future holds for this emerging technology.
We will be discussing:
• Is AI the right move for oncology care?
• What is the impact on patient care and our patient expert’s experience?
• And how can we learn more about AI?

Guest:
Dr. Sandip Patel, is a professor of Medicine at UCSD and a nationally recognized leader in precision cancer medicine and innovation. He specializes in early-phase clinical trials and immunotherapy, with a focus on developing innovative treatments for patients with advanced lung cancer. Today, we’re excited to welcome him to the podcast to discuss the future of AI in cancer care, in general, and in thoracic oncology in particular.